- Home
- FF vs ELDN Comparison
FF vs ELDN Comparison
Compare FF & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FF
- ELDN
- Stock Information
- Founded
- FF N/A
- ELDN 2004
- Country
- FF United States
- ELDN United States
- Employees
- FF N/A
- ELDN N/A
- Industry
- FF Major Chemicals
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- FF Industrials
- ELDN Health Care
- Exchange
- FF Nasdaq
- ELDN Nasdaq
- Market Cap
- FF N/A
- ELDN 232.4M
- IPO Year
- FF N/A
- ELDN N/A
- Fundamental
- Price
- FF $4.16
- ELDN $3.35
- Analyst Decision
- FF Strong Buy
- ELDN Strong Buy
- Analyst Count
- FF 1
- ELDN 1
- Target Price
- FF $0.80
- ELDN $16.00
- AVG Volume (30 Days)
- FF 316.7K
- ELDN 261.8K
- Earning Date
- FF 03-28-2025
- ELDN 03-20-2025
- Dividend Yield
- FF 5.77%
- ELDN N/A
- EPS Growth
- FF N/A
- ELDN N/A
- EPS
- FF 0.35
- ELDN N/A
- Revenue
- FF $243,339,000.00
- ELDN N/A
- Revenue This Year
- FF N/A
- ELDN N/A
- Revenue Next Year
- FF N/A
- ELDN N/A
- P/E Ratio
- FF $11.89
- ELDN N/A
- Revenue Growth
- FF N/A
- ELDN N/A
- 52 Week Low
- FF $4.08
- ELDN $1.52
- 52 Week High
- FF $8.36
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- FF 38.44
- ELDN 33.23
- Support Level
- FF $4.08
- ELDN $3.22
- Resistance Level
- FF $4.44
- ELDN $3.63
- Average True Range (ATR)
- FF 0.16
- ELDN 0.19
- MACD
- FF 0.03
- ELDN -0.00
- Stochastic Oscillator
- FF 19.05
- ELDN 21.67
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.